Cetriler D

Quick links to important sections

Cetriler D

Method of action: Antitussive, Nasal Preparations

Treatment option: Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetriler D

Property Description
Active ingredient Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride
Form Extended-Release Tablet (Oral)
Pharmacological class Antihistamine/Nasal Decongestant Combination
Common use Relief of upper respiratory allergy symptoms and congestion
Origin Synthetic

What Type of Medicine is Cetriler D?

Cetriler D is defined as a combination drug belonging to the Upper Respiratory Combinations pharmacological class, used for oral administration. This synthetic medicine is a fixed-dose pairing of two distinct active entities: the antihistamine Cetirizine Hydrochloride and the decongestant Pseudoephedrine Hydrochloride. The typical dosage form is an Extended-Release Tablet, which is a key design feature ensuring the active components are released over a prolonged period for sustained symptomatic management. This sustained action is designed to maintain consistent relief from both allergic symptoms and congestion throughout the day.

Active Ingredients and Dual Purpose

The therapeutic aim of Cetriler D is achieved by addressing the allergic trigger and the resulting physical symptom of congestion simultaneously. This approach is utilized for providing comprehensive therapeutic benefits compared to using single drug treatments in allergic rhinitis.

Cetirizine Hydrochloride is specifically a second-generation H1-receptor antagonist. This molecule is designed to selectively block the effects of histamine, the substance responsible for common allergy symptoms, without the high sedation risk associated with older antihistamine generations. The second ingredient, Pseudoephedrine Hydrochloride, is a sympathomimetic agent acting as a nasal decongestant. The purpose of this component is to physically relieve blockage by promoting vasoconstriction within the nasal lining, shrinking swollen tissues and facilitating easier breathing. The dual composition makes it a primary choice for managing acute episodes where simultaneous histaminic irritation and physical swelling necessitate intervention, such as during periods of high pollen counts.

What side effects are possible with Cetriler D?

Possible Side Effects and Safety Information

The safety profile for the cetirizine hydrochloride/pseudoephedrine hydrochloride combination is officially documented by frequency and affected body system, reflecting data from regulatory sources.

Frequency-Classified Adverse Reactions

The most frequently documented effects, classified as Common, often include Nervous System Disorders such as somnolence, fatigue, and dizziness, alongside Psychiatric Disorders like insomnia, and Gastro-intestinal Disorders like dry mouth. Rare adverse reactions documented in regulatory sources include syncope, convulsions, tachycardia, confusion, and abnormal hepatic function.

Reactions categorized as Very Rare or Not Known (frequency cannot be estimated) involve serious concerns such as Anaphylactic shock, Ischaemic colitis, and severe skin reactions. Furthermore, rare neurovascular events, including Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), have been associated with the decongestant component.

Safety-Related Restrictions and Considerations

The medicine is subject to several strict safety constraints defined in official labeling. It is contraindicated in patients with severe uncontrolled Hypertension or severe Coronary Artery Disease. Use is strictly forbidden during, or within 14 days of stopping, therapy with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of hypertensive crisis.

Special safety considerations are documented for certain groups. Individuals with renal or hepatic impairment may require dosage adjustment due to altered drug clearance. Additionally, older adults may exhibit increased sensitivity to effects such as rapid heart rate, dizziness, or urinary retention. Finally, pruritus (severe itching) has been reported upon discontinuation following long-term use of the cetirizine component.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation defines the overdose profile of Cetriler D (Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride) by the potential for severe, life-threatening manifestations, requiring immediate medical attention.

Documented Manifestations and Serious Outcomes

System Documented Overdose Signs
Central Nervous System (CNS) Hallucinations, confusion, seizures (convulsions), extreme drowsiness, and restlessness are listed potential effects.
Cardiovascular System Severe outcomes include very high blood pressure (hypertension) and various forms of irregular or fast heart rate (arrhythmia/tachycardia), as documented in official labeling.

Required Emergency Actions

Government regulatory guidance explicitly mandates that immediate emergency help must be sought if any symptoms of overdose are suspected. Overdose is classified as an event with potential for severe and life-threatening effects. The labeling requires individuals to get medical help or contact a Poison Control Center right away.

Management and Considerations

Treatment is defined as symptomatic and supportive, as no specific antidote is known for this combination. Regulatory documents note that special consideration is warranted for certain groups, as the use of similar medicines in children under 4 years of age has been associated with serious or possibly life-threatening effects. The total ingested dose of both the antihistamine and the decongestant component is a critical factor in determining the severity of the overdose.

Therapeutic Uses of Cetriler D

What Cetriler D Treats: Main Uses and Benefits

Cetriler D is commonly used for the supportive management of upper respiratory symptoms associated with hay fever or other upper respiratory allergies. The medicine is applied in therapeutic areas where relief from combined allergic and congestive symptoms is appropriate. This combination is relevant for easing symptoms related to inflammatory or irritative states, which may become more disruptive during seasonal or acute flare-ups.

It is primarily considered for managing symptom clusters that may become intense or disruptive, including frequent sneezing, bothersome runny nose (rhinorrhea), and irritating itchy, watery eyes, alongside significant nasal and sinus blockage.

“The combination assists with easing the symptom load during episodes where both irritation and obstruction are pronounced.”

The extended-release formulation is relevant across conditions presenting with acute episodes or periods of heightened symptoms. It is commonly used during phases of increased distress, offering sustained symptomatic assistance that helps patients cope more steadily with symptom fluctuations and supports general well-being.

Quick Fact: Relief for Combined Symptoms
Primary Domain: Allergic Rhinitis with significant Nasal Congestion.
Benefit Focus: Simultaneous relief of allergic irritation and physical congestion.
Scenario: Relevant when acute symptoms interfere with routine activities.

Regulatory References

  1. DailyMed Label for Cetirizine HCl and Pseudoephedrine HCl Extended-Release Tablets

Eligibility and Restrictions for Use

Cetriler D (Cetirizine/Pseudoephedrine) eligibility is determined by specific regulatory exclusions, primarily due to the sympathomimetic component, pseudoephedrine.

Contraindications (Must Not Use)

Condition / Population Official Status
Severe or uncontrolled high blood pressure Contraindicated
Severe coronary artery disease (Ischaemic heart disease) Contraindicated
Severe kidney failure (C Cr le 15 mL/min / Dialysis) Contraindicated
Concurrent/Recent use of MAOIs (within 14 days) Contraindicated
Known hypersensitivity to ingredients (including hydroxyzine) Contraindicated

Restricted and Age-Related Use

Use is not recommended or not established for children under 12 years of age for the combination product. For patients with moderate kidney or liver impairment, the regulatory label requires a mandatory dose reduction.

Pregnancy and Lactation

Official labeling indicates limited data on the combination product in pregnancy. Use is generally not recommended during breastfeeding due to the presence of pseudoephedrine, which carries a risk of effects on the infant and potential to reduce milk supply.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug and drug-substance interactions for Cetriler D, which is a combination of the antihistamine cetirizine and the decongestant pseudoephedrine. These interactions dictate co-administration requirements and constraints.

Interaction Category Practical Constraint
Monoamine Oxidase Inhibitors (MAOIs) Do not combine. The use of Cetriler D is strictly contraindicated during or within 14 days of stopping MAOI therapy. This restriction applies to medicines such as Isocarboxazid, Phenelzine, Selegiline, and Tranylcypromine.
Central Nervous System (CNS) Depressants Avoid concurrent use with alcohol, sedatives, opioids, or other CNS depressants, as this may result in additive CNS depression and increased impairment of alertness.
Other Sympathomimetics Use with caution. Co-administration with other decongestants or sympathomimetic agents may increase the risk of adverse cardiovascular or CNS effects due to additive adrenergic stimulation.

For the cetirizine component, a small decrease in clearance has been noted with co-administration of Theophylline at higher doses. Additionally, the elimination of both components may be reduced in patients with renal or liver impairment, requiring consideration during prescribing. In all cases, co-administration should only occur under the guidance of a healthcare professional.

Mechanism of Action

How Cetriler D Works: Mechanism of Action

Cetriler D exerts its effects through the co-modulation of two distinct physiological pathways.

Modulating the Histamine Pathway

This domain covers the action of the cetirizine component, which acts as a selective antagonist at the histamine H1 receptor to block mediator binding. By interrupting this signaling cascade, the drug limits the histamine-driven increase in vascular permeability and subsequent extravasation of plasma into tissues.

Activating alpha-Adrenergic Receptors

This mechanism belongs to the pseudoephedrine component, which acts as an agonist on alpha-adrenergic receptors found on blood vessel walls. This activation causes vasoconstriction (narrowing of vessels), which physically decreases the blood volume and tissue volume in the mucosal lining, resulting in reduced airflow impedance.

Complementary Physiological Effects

The drug's overall mechanistic profile is shaped by the simultaneous operation of these two non-overlapping mechanisms—one modulates the humoral mediator response, and the other directly regulates sympathetic vascular tone. This multi-target pathway modulation influences both mediator signaling and vascular tone, leading to a combined effect on local fluid homeostasis and tissue size modulation.

Dosage and Administration Information

How to Use Cetriler D

This section outlines the administration principles and dosage patterns for Cetriler D, which is the fixed-dose combination of Cetirizine Hydrochloride (antihistamine) and Pseudoephedrine Hydrochloride (decongestant).


Administration Scope

Property Instruction
Route of administration Oral (by mouth).
Dosing schedule One Extended-Release Tablet (5 mg/120 mg). The total daily dose must not exceed two tablets (10 mg/240 mg total) in a 24-hour period.
Timing in relation to meals May be taken with or without food.
Age-group rules Approved for adults and children 12 years of age and older. Use in older adults (65+ years) or those with renal or hepatic impairment requires consultation with a healthcare provider for dose adjustment.
Missed-dose rules If a dose is missed, take it when remembered; if it is near the next dose, the missed dose should be skipped. The dose must not be doubled.

Procedural Structure and Frequency

Usage Pattern: The medicine is designed for a twice-daily regimen. The Extended-Release Tablet must be administered every 12 hours to maintain consistent levels of both components.

Special Procedural Conditions: To ensure the proper release of the extended-release component, the tablet must be swallowed whole. It must not be broken, crushed, or chewed.


Connection to the overall use protocol: The administration protocol establishes a strict, standardized twice-daily schedule based on the Extended-Release Tablet form. This structure governs the maximum 24-hour dose and mandates the preservation of the tablet’s physical integrity by prohibiting crushing or chewing. Compliance with this sequence defines the usage pattern for temporary relief.

Recent Clinical Evidence

Evidence for use in Seasonal and Perennial Allergic Rhinitis with Nasal Congestion

The core research for this combination medicine involves short-term, randomized, double-blind, placebo-controlled trials (RCTs) used in exploring how symptoms change over time in adults and adolescents. Studies monitored patient-reported outcomes describing perceived discomfort, tracking changes in common allergy complaints like sneezing, runny nose, and nasal obstruction, and explored comparisons to the individual components evaluated separately.

Research on Symptom Relief and Onset of Action

Specialized studies, including those using controlled Environmental Challenge Chambers (ECCs), were utilized to evaluate the time it takes for initial changes in symptom measurements to occur. Research describes that observed changes in symptom measurements began within the first few hours following a single dose, noting that these results reflect the specific controlled conditions under which they were conducted.

Evidence in Patients with Concomitant Mild-to-Moderate Asthma

Dedicated randomized trials have explored this combination in a specific subgroup of patients who also have stable, mild-to-moderate asthma, monitoring concurrent measurements of allergic rhinitis and asthma symptom scores, and outcomes reflecting daily functioning.

Long-term Studies and Follow-up

The follow-up durations for key clinical research were primarily limited to short-term course evaluations of two to four weeks. Consequently, long-term effects are not fully established, and studies examining outcomes over extended timeframes are not well characterized.

Evidence in Special Populations

The primary study populations were adults and adolescents (ages 12 years and older), and results apply only to the populations studied in the main clinical trials. Data show patterns related to certain groups remaining insufficiently studied, as few dedicated data are available for older adults (age 65 years and above) in the combination product's research.

What Is Still Uncertain About Cetriler D

The research describes that follow-up durations were limited across the evidence base, meaning there is limited information for long-term outcomes. Furthermore, the evidence specific to patients with concomitant asthma is limited to those with stable, mild-to-moderate conditions, and the research does not provide insight into individuals with more severe or unstable respiratory conditions.

Key Studies & References

  1. ZYRTEC-D ALLERGY PLUS CONGESTION (Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride) Extended-Release Tablets - DailyMed Label

Frequently Asked Questions (FAQ)

Common questions about Cetriler D (FAQ)


Q: What is the main difference between Cetriler D and regular Cetriler?

Cetriler D is described in official product information as a combination product that contains two active components: the antihistamine Cetirizine Hydrochloride and the nasal decongestant Pseudoephedrine Hydrochloride. Products referred to as 'regular' cetirizine typically contain only the antihistamine component.

Q: Does Cetriler D contain a steroid?

No. The official labeling lists the active ingredients as Cetirizine Hydrochloride (an antihistamine) and Pseudoephedrine Hydrochloride (a nasal decongestant). Regulatory sources do not list steroids as an active component in this fixed-dose combination.

Q: Why is vitamin D included in the Cetriler D formulation?

Official product information states that the active components in this medicine are the antihistamine Cetirizine and the decongestant Pseudoephedrine. Vitamin D is not listed as an active ingredient in the Cetriler D formulation.

Q: How is Cetriler D different from a common cold remedy?

Cetriler D is specifically indicated for the temporary relief of symptoms associated with allergic rhinitis (allergies), using the component Cetirizine to target the allergic response and Pseudoephedrine to help with nasal swelling. Common cold remedies may contain different ingredients and are not always formulated to address the underlying allergic trigger.


Q: Can Cetriler D affect my mood or anxiety levels?

Official drug labeling lists adverse reactions that affect the nervous and psychiatric systems, which can include insomnia (difficulty sleeping) and, less commonly, reports of agitation or anxiety. These effects are among those reported in association with the drug during clinical trials or post-market surveillance.

Q: Are there any dietary restrictions while taking Cetriler D?

Regulatory documents advise avoiding the concurrent use of alcohol due to the risk of increased sedation and impairment. The product label also states the medicine may be taken with or without food, and no other common food-based restrictions are generally specified in regulatory documents.

Q: Can I take Cetriler D with common pain relievers like ibuprofen?

Official regulatory documents do not list specific interactions with common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or acetaminophen. However, official information indicates that co-administration with any other medicine should be discussed with a healthcare provider.

Q: Can Cetriler D interact with antifungal or antibiotic medications?

The label does not list a specific interaction between this combination product and most common antifungal or antibiotic medications. However, the clearance of the cetirizine component can be slightly affected by certain other medications. Regulatory sources advise that all concurrent medication use be reviewed by a healthcare provider.


Q: Is Cetriler D over-the-counter or does it require a prescription?

The product is generally classified by regulatory bodies for use without a prescription. However, due to the presence of the decongestant component, Pseudoephedrine, its retail sale is typically federally regulated and subject to certain quantity restrictions.

Q: Is there a generic version of Cetriler D?

Yes, the medication is available under its generic name, which is the combination of Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride in extended-release tablet form, in addition to various brand names.

Q: What are the inactive ingredients in Cetriler D?

The complete list of inactive ingredients (excipients) is detailed in the official product labeling and can vary by manufacturer. Common inactive ingredients often include substances such as magnesium stearate, cellulose derivatives, and frequently lactose monohydrate.

Q: Does Cetriler D contain lactose or other common allergens?

Many official formulations of this medicine list lactose monohydrate among the inactive ingredients. If there are known allergies or intolerances, regulatory sources advise reviewing the specific product packaging or seeking guidance from a healthcare professional for a complete list of all inactive ingredients.


Q: Is Cetriler D effective for chronic hives?

The official indication for the combination product Cetriler D is limited to the temporary relief of symptoms associated with allergic rhinitis (hay fever) and nasal congestion. The regulatory label does not list chronic hives (chronic urticaria) as an indicated use for this specific combination product.

Q: Why is Cetriler D not recommended for patients with certain eye conditions?

The Pseudoephedrine component is a sympathomimetic agent, meaning it acts on the sympathetic nervous system. Official prescribing information advises caution or avoidance in patients with conditions like narrow-angle glaucoma because this component can potentially exacerbate (worsen) that condition.

Q: Is there any risk of dependence with Cetriler D?

The product is not listed as a federally scheduled controlled substance (Schedule I–V) in the US, which typically indicates a high risk of dependence. However, due to the regulatory status of the decongestant component, Pseudoephedrine, its sale and purchase are regulated by law to prevent misuse.

Q: What is the regulatory classification of Cetriler D (e.g., Schedule 4)?

This product is classified as a non-scheduled Over-The-Counter (OTC) drug in the US. However, due to its contents, the Pseudoephedrine component is regulated as a List I chemical under the Combat Methamphetamine Epidemic Act, which imposes restrictions on the product's sales.


Q: Is Cetriler D safe to take for long periods?

Official regulatory documents state that the follow-up duration for the key clinical research was primarily limited to short-term course evaluations (typically two to four weeks). Consequently, information regarding the effects and safety of using this medicine over extended timeframes is not well characterized or fully established in the primary research base.

Q: Can I take Cetriler D with my blood pressure medication?

Regulatory information lists severe or uncontrolled high blood pressure as a contraindication (a condition where the drug must not be used). This restriction highlights the cardiovascular risk of the decongestant component. Official regulatory sources indicate that any co-administration should be discussed with a healthcare provider.

Q: Is it okay to drive after taking Cetriler D?

Official product information lists common adverse reactions such as somnolence (drowsiness) and dizziness. Furthermore, regulatory sources warn that combining it with CNS depressants or alcohol may result in increased impairment of alertness. Official documents state that individuals may experience these effects, and regulatory sources advise caution when undertaking tasks requiring mental alertness, such as operating machinery or driving.

Q: What happens if I stop taking Cetriler D suddenly?

Regulatory information generally does not address the overall process of discontinuation. However, reports related to the cetirizine component note that the condition of pruritus (severe itching) has been reported upon sudden discontinuation following long-term use.

Q: What is the maximum duration of treatment described in official prescribing information?

While the official label describes a required twice-daily regimen, the regulatory literature on the combination product primarily focuses on short-term use. Research follow-up for key clinical trials was limited to two to four weeks, meaning there is limited data to characterize outcomes beyond short-term use.

Q: What specific clinical trials support the use of Cetriler D?

Official research evidence describes the supportive studies as primarily short-term, randomized, double-blind, placebo-controlled trials (RCTs) conducted on adults and adolescents. While the exact names and identifiers of the specific clinical trials are not listed in the patient-facing materials, the official research evidence provides a description of the types of studies conducted.

How should Cetriler D be stored and disposed of?

How to Store and Dispose of Cetriler D?

Official regulatory guidelines define strict conditions for the storage and disposal of this medicine, focusing on maintaining stability and public safety.

Storage & Disposal Scope Official Regulatory Information
Storage Temperature Store at USP Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Handling & Protection Keep the tablets away from excess heat and moisture; do not freeze.
Container Rules Keep the product in its original container, tightly closed. Do not use if the bottle seal or blister unit is open or torn.
Child Safety Keep out of the sight and reach of children and pets; store in a secure, elevated location.
Disposal Instructions Dispose of unused or expired medicine using a drug take-back program as the preferred method.
Wastewater Restriction Do not flush the medication down a toilet or drain, as it is not on the FDA list for flushing.

These constraints ensure the product remains stable until its labeled expiration date. For at-home disposal when a take-back program is unavailable, the official method requires mixing the product with an undesirable substance (e.g., dirt) in a sealed bag before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetriler D found in:

A-Z Index: